Poster Central Dermatology, Saint Louis, Missouri, USA; 2 ICON Epidemiology, Vancouver, British Columbia, Canada;

Similar documents
Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Details of UNCOVER-2 and UNCOVER-3 Study Results Published in The Lancet

Kim A. Papp, MD PhD Probity Medical Research, Waterloo, ON, Canada

Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry

DLQI (ESTEEM

Eli Lilly and Company

Jashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7

Incorporating Biologics Into Your Practice

Summer AAD Summer AAD Support provided by LEO Pharma A/S. Poster nº

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)

PGA x BSA as a PASI Surrogate

Source: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California

Ixekizumab for treating moderate to severe plaque psoriasis [ID904]

Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease

Psoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid

JEADV SHORT REPORT. Abstract

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis

The 73rd Annual Meeting of the American Academy of Dermatology, San Francisco ; March 20-24, 2015 Poster ID: 909

ixekizumab 80mg solution for injection (Taltz ) SMC No. (1223/17) Eli Lilly and Company Ltd.

Psoriasis: Therapeutic goals

Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission

Scottish Medicines Consortium

Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3

Horizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209

Update on systemic therapies and emerging treatments How do I choose a systemic agent?

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar

Insights from the Kaiser Permanente database

Formulary Decisions and the Evolution of Psoriasis Treatment

The New and Emerging Agents: Dermatology

Abstract Background: Methods: Results: Conclusion:

Background AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

Faculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA

ICER Public Meeting: Evaluating Emerging Therapies for Psoriasis and Endometriosis

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Synopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier

Glenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;

5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris

Criteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or

Approximately 3% of the US adult population,

Clinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:

Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis

The Cosentyx clinical trial programme 1-11

Daily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment

P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling

Proof-of-Concept Phase-2a Clinical Trial of ANB020 (Anti-IL-33 Antibody) in the Treatment of Moderate-to-Severe Adult Atopic Dermatitis

Biologics and Psoriasis: The Beat Goes On

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18

Clinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 11.18

Disclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab

Research Developments in Psoriasis Treatment A CME Activity

BIOLOGICS THE KEY TO NEXT GENERATION DERMATOLOGY R&D?

Comparing Multiple-Choice, Essay and Over-Claiming Formats as Efficient Measures of Knowledge

Psoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center

BJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add? CLINICAL TRIAL

Horizon Scanning Centre May Brodalumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 5524

Initiation and evaluation of the effect of biologic treatment. ActaDV ActaDV

Proof-of-Concept Phase-2a Clinical Trial of ANB020 (Anti-IL-33 Antibody) in the Treatment of Moderate-to-Severe Adult Atopic Dermatitis

Skin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France

Brodalumab for treating moderate to severe plaque psoriasis [ID878]

The role of current biologic therapies in psoriasis

Risankizumab (by subcutaneous injection) for moderate to severe chronic plaque psoriasis

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Bilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)

chemotherapeutic agents in

University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2

See Important Reminder at the end of this policy for important regulatory and legal information.

Ixekizumab (plaque psoriasis)

Biologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre

ESPONDILOARTROPATÍAS. Dr. Julio Ramírez García

Ixekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι

New Drug Evaluation: ixekizumab injection, subcutaneous

75th AAD Annual Meeting

Atopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

JEADV ORIGINAL ARTICLE. Abstract

Rheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17

Snapshot Dx Quiz: September 2018 Detailed Answers

Siliq. Siliq (brodalumab) Description

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

Secukinumab (plaque psoriasis)

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Targeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Cost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis

STELARA (ustekinumab)

Patients Perspective on the Impact of Moderate-to-Severe Genital Psoriasis

The Treatment Toolbox for Severe Pediatric Psoriasis

Project Title Community Pharmacy Participation in Health Screening and Medication Therapy Management

From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment

Cosentyx. Cosentyx (secukinumab) Description

Transcription:

Poster 8211 Disease Severity and Quality of Life among Ixekizumab- Treated Psoriasis Patients in the Real-World Setting: Results from a Single US Dermatology Referral Practice Craig Leonardi 1, Aleksandra Gara 2, David Amato 3, Katherine Osenenko 2, Solmaz Setayeshgar 2, Sisi Wang 2, Mwangi J. Murage 3, Chen-Yen Lin 3, William N. Malatestinic 3 1 Central Dermatology, Saint Louis, Missouri, USA; 2 ICON Epidemiology, Vancouver, British Columbia, Canada; 3 Eli Lilly and Company, Indianapolis, Indiana, USA American Academy of Dermatology Annual Meeting, Washington D.C. March 1-5, 2019 This study was sponsored by Eli Lilly and Company.

Objective and Methods Objective Assess disease severity and quality of life (QoL) at 3-month intervals over the first year of ixekizumab (IXE) treatment among psoriasis patients at a single US dermatology referral practice. Study Design Retrospective observational cohort study, using chart review methodology. Setting Single US dermatology referral practice in Saint Louis, MO. Population Adult psoriasis patients initiating IXE (index) between March 22, 2016 (IXE approval date) and February 28, 2017. Exclusion criteria: Any prior IXE treatment, or any clinical trial participation during study period. Data Collection Data were collected from medical charts, for the year prior to index and from index until Feb.28, 2018, or IXE discontinuation, whichever was first. Statistical Analyses Summary statistics were generated for patient characteristics and prior treatments received. Body surface area (BSA), static Physician Global Assessments (spga) and Dermatology Quality of Life (DLQI) were summarized at 1 month post-index and at 3-month intervals pre and post-index. Post-index results are presented here for patients with data available at each time point (+/- 45 days).

Results (1) Patient characteristics A total of 106 psoriasis patients were included, with mean disease duration of 14.5 years at index. Median age 47.9 years, 93% Caucasian, 67% male, 95% privately insured. Treatment history At index, 74% (n=78) of patients had received prior biologic therapy for psoriasis, predominantly with a TNF-α inhibitor (n=47), secukinumab (n=27) and/or ustekinumab (n=12). Approximately half had received prior systemic treatment (52%), such as methotrexate, and/or topical treatment (51%). Table 1. Disease severity (spga) at index and post-index time points for psoriasis patients treated with ixekizumab. spga score distribution (N=106) 1 1 month 2 (N=95) 1 3 months 3 (N=100) 1 6 months 3 (N=87) 1 9 months 3 (N=80) 1 12 months 3 (N=72) 1 0 Clear 3 (2.8) 28 (29.5) 53 (53.0) 41 (47.1) 40 (50.0) 28 (38.9) 1 Almost clear 5 (4.7) 28 (29.5) 21 (21.0) 8 (9.2) 17 (21.3) 17 (23.6) 2 Mild 20 (18.9) 31 (32.6) 15 (15.0) 23 (26.4) 10 (12.5) 17 (23.6) 3 Mild to moderate 12 (11.3) 1 (1.1) 2 (2.0) 3 (3.5) 2 (2.5) 2 (2.8) 4 Moderate 44 (41.5) 6 (6.3) 5 (5.0) 6 (6.9) 7 (8.8) 5 (6.9) 5 Moderate to severe 17 (16.0) 0 (0.0) 2 (2.0) 5 (5.8) 4 (5.0) 2 (2.8) 6 Severe 1 (0.9) 0 (0.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) Unknown 4 (3.8) 1 (1.1) 1 (1.0) 1 (1.2) 0 (0.0) 1 (1.4) Abbreviations: n=number; spga = Static physician global assessment.

Results (2) Table 2. Disease severity (BSA) at index and post-index time points for psoriasis patients treated with ixekizumab. BSA Distribution (N=106) 1 1 month 2 (N=95) 1 3 months 3 (N=100) 1 6 months 3 (N=87) 1 9 months 3 (N=80) 1 12 months 3 (N=72) 1 1 % (NPF T2T) 20 (18.9) 66 (69.5) 84 (84.0) 71 (81.6) 68 (85.0) 59 (81.9) <3% (Mild) 12 (11.3) 11 (11.6) 6 (6.0) 4 (4.6) 2 (2.5) 3 (4.2) 3%-10% (Moderate) 58 (54.7) 16 (16.8) 8 (8.0) 10 (11.5) 7 (8.8) 6 (8.3) >10% (Severe) 12 (11.3) 1 (1.1) 1 (1.0) 1 (1.2) 3 (3.8) 3 (4.2) Unknown 4 (3.8) 1 (1.1) 1 (1.0) 1 (1.2) 0 (0.0) 1 (1.4) Abbreviations: BSA=Body surface area; n=number; NPF T2T=National Psoriasis Foundation treat to target. Table 3. Health-related quality of life (DLQI) at index and post-index time points for psoriasis patients treated with ixekizumab. 1 month DLQI score 3 months 3 6 months 3 9 months 3 12 months 3 (N=106) (Effect on patient s life) (N=95) 1 (N=100) 1 (N=87) 1 (N=80) 1 (N=72) 1 0-1: No effect 22 (20.8) 53 (55.8) 67 (67.0) 51 (58.6) 48 (60.0) 48 (66.7) 2-5: Small effect 40 (37.7) 29 (30.5) 15 (15.0) 24 (27.6) 20 (25.0) 11 (15.3) 6-10: Moderate effect 21 (19.8) 9 (9.5) 9 (9.0) 8 (9.2) 7 (8.8) 6 (8.3) 11-20: Very large effect 14 (13.2) 4 (4.2) 7 (7.0) 4 (4.6) 4 (5.0) 5 (6.9) 21-30: Extremely large effect 5 (4.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Unknown 4 (3.8) 0 (0.0) 2 (2.0) 0 (0.0) 1 (1.3) 2 (2.8) Abbreviations: n=number; DLQI=Dermatology life quality index.

Results and Conclusions Results Speed of onset By 1 month (n=95, data available), more than half of patients (59%) had clear or almost clear skin (spga 0,1) and more than two-thirds (70%) had BSA 1%. By 3 months (n=100), nearly three-quarters of patients (74%) had spga 0,1, while 84% had BSA 1%. Duration of response At 12 months (n=72), 63% of patients had spga 0,1 and 82% had BSA 1%. At each time point, the median decrease from index was approximately 3% for BSA and about 2 points each for spga and DLQI scores (data not shown). IXE treatment continuation At 12 months, 74% (n=78) of patients in the cohort continued to receive treatment with ixekizumab (data not shown). Figure 1. Percentage of ixekizumab-treated psoriasis patients achieving target BSA ( 1%), spga (0,1), and DLQI (0,1) levels. Conclusions In this real-world cohort of IXE-treated psoriasis patients at a US dermatology referral practice, more than half of patients achieved clear skin (spga 0) at 3 months, and more than 80% met National Psoriasis Foundation (NPF) targets for BSA ( 1%) at 3 months and at every 6 month assessment. Improvements in disease severity (BSA, spga) and QoL (DLQI) were sustained over the first year of IXE treatment. Findings should be confirmed in larger multi-site studies. Disclosures: The study was sponsored by Eli Lilly and Company. Medical writing services were provided by ICON plc, and were funded by Eli Lilly and Company. C. Leonardi has received honoraria from Eli Lilly for the following: Advisory Board, Speaker, Consultant. AG, KO, SS, SW are employees of ICON plc., a company contracted by Eli Lilly to conduct this study. DA, MJM, C. Lin, and WNM are employees of Eli Lilly.